Vancouver, BC – October 29, 2018: Medipure Pharmaceuticals Inc., a biopharmaceutical incubator committed to discovering and developing proprietary endocannabinoid system-based prescription drugs for targeted diseases by regulating specific molecular mechanisms, today announced the appointment of Dr. Dubravko Kičić as Director of Operations for its Croatian subsidiary.
With an extensive history in Research and Development, Dr. Kičić will play a significant role in leading the work associated with clinical trials and pharmacology. In addition to the development of full analytical labs, the Croatian site will house a GMP facility allowing the Company to produce drugs in compliance with the European regulatory standards necessary to support clinical trials on the road to regulatory approvals and commercialization.
Dr. Kičić holds a Bachelor of Science in Physics from the University of Zagreb, a Doctoral Degree of Science in Biotechnology from the Helsinki University of Technology, along with an Executive Master of Business Administration from the Aalto Executive Business School in Helsinki.
For more information, please visit: http://medipurepharmaceuticals.com
Medipure Pharmaceuticals is a biopharmaceutical incubator committed to discovering and developing proprietary endocannabinoid system-based prescription drugs for targeted diseases by regulating specific molecular mechanisms. Our core products target specific disease areas including pain management, mood disorders/anxiety, nausea, appetite, oncology, arthritis, dermatology and fatty liver disease (NASH). Medipure Pharmaceuticals’ research and development is focused on having the greatest impact and benefit for patients worldwide. At the same time, we aim to make sure that our products are approved by regulators and well understood by physicians, healthcare providers and prospective patients.